Author

G. Bridon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:experimental assay· 1 Assay:metabolomics· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

D. Avizonis· 2 shared A. Gariepy· 1 shared A. O. Donayo· 1 shared C. Greenwood· 1 shared I. Topisirovic· 1 shared J. St-Pierre· 1 shared J. Ursini-Siegel· 1 shared K. S. Williams· 1 shared

Activity by Year

2017-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Avizonis

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Repression of LKB1 by miR-17~92 sensitizes MYC-dependent lymphoma to biguanide treatment

S. Izreig, A. Gariepy, A. O. Donayo, G. Bridon, D. Avizonis, R. D. Sheldon, R. Laister, M. D. Minden, N. A. Johnson, K. S. Williams, M. S. Rudoltz, T. F. Duchaine, S. Yoo, M. N. Pollak, R. G. Jones

The paper shows that miR-17~92 expression in Myc+ tumors increases sensitivity to biguanide treatment by disrupting bioenergetic stability in lymphoma cells.

bioRxiv · Dec 20, 2019Cancer Biology

Translational and HIF1α-dependent metabolic reprograming underpin oncometabolomeplasticity and synergy between oncogenic kinase inhibitors and biguanides.

L. Hulea, S.-P. Gravel, M. Morita, M. Cargnello, O. Uchenunu, Y. K. Im, S. McLaughlan, O. Larsson, M. Ohh, T. Ferreira, C. Greenwood, G. Bridon, D. Avizonis, J. Ursini-Siegel, J. St-Pierre, , I. Topisirovic

This study identifies translational reprogramming of non-essential amino acid synthesis and HIF1-dependent reductive glutamine metabolism as key factors enabling synergy between kinase inhibitors and biguanides in cancer cells.

bioRxiv · Jul 8, 2017Cancer Biology